[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631221":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":22,"locations":10,"responsibleParty":27,"collaborators":10,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":35,"eligibilityCriteria":36,"healthyVolunteers":31,"sex":37,"minAge":38,"maxAge":10,"enrollmentInfo":39,"targetDuration":10,"studyType":42,"phases":10,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":10},{"fullName":5,"class":6},"Pfizer","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Rimegepant sulfate",null,[12],"Drug: Rimegepant sulfate",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":10},"DRUG","ALL Who treated with Rimegepant sulfate",[9],[19],{"name":20,"affiliation":5,"role":21},"Pfizer CT.gov Call Center","STUDY_DIRECTOR",[23],{"name":20,"role":24,"phone":25,"phoneExt":10,"email":26},"CONTACT","1-800-718-1021","ClinicalTrials.gov_Inquiries@pfizer.com",{"type":28,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100631221","a-study-to-learn-about-the-study-medicine-nurtec-odt-75-mg-after-it-is-released-into-the-markets-in-korea-100631221",false,"NCT07497854","A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea","A Post-marketing Surveillance (PMS) Study to Evaluate the Safety and Effectiveness of NURTEC® ODT 75 mg (Rimegepant Sulfate) in Adult Migraine Patients in Korea.","Rimegepant PMS","Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:\n\n1. Subjects aged 19 years or older\n2. Subjects who administered NURTEC® ODT 75 mg (Rimegepant sulfate) according to the approved label\n3. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.","ALL","19 Years",{"count":40,"type":41},3000,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate safety and effectiveness of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine during the PMS period as required by the Korean ministry of food and drug safety (MFDS).",[45],"Migraine With or Without Aura",[9,47,48],"safety","efficacy","NOT_YET_RECRUITING","2026-05-12",{"date":52,"type":53},"2026-05-15","ACTUAL",{"date":55,"type":41},"2026-10-01",{"date":57,"type":41},"2030-08-01",{"name":5,"class":6}]